. Author manuscript; available in PMC: 2014 Feb 5.

Published in final edited form as: Cancer Chemother Pharmacol. 2008 May 22;63(3):517–524. doi: 10.1007/s00280-008-0769-8

Table 1.

Comparison of pharmacokinetic parameters for APC, irinotecan, SN-38, and SN-38G using non-compartmental analysis

	APC	Irinotecan	SN-38	SN-38G
Tmax (h)	2.31 ± 0.56	1.3 ± 0.3	1.2 ± 0.4	1.66 ± 0.28
Cmax (ng/mL)	178.6 ± 94.5	1,465 ± 598	12.9 ± 5.5	65.3 ± 25.7
Half-life (h)	5.5 ± 1.08	5.3 ± 0.86	8.5 ± 6.4	10.0 ± 2.9
AUC_0–24 (ng h/mL)	1,337 ± 506	4,303 ± 1,321	63.9 ± 39.7	359 ± 157
AUC_0–inf (ng h/mL)	1,423 ± 565	4430 ± 1306	76.7 ± 50.5	440 ± 197
AUC % extrapolated	5.7 ± 5.0	3.1 ± 3.2	19.8 ± 11.1	16.7 ± 9.5